ArticlePloS one2017
Cold Atmospheric Plasma, Created at the Tip of an Elongated Flexible Capillary Using Low Electric Current, Can Slow the Progression of Melanoma.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- A dual-index framework for cold atmospheric plasma dosing: A meta-analysis of parametric control from volumetric redox flux to redox homeostatic status.Redox biology · 2026Pooled it
- Advances in cold atmospheric plasma therapy for cancer.Bioactive materials · 2025Review
- Gas Plasma Combination Therapies-Promises from Preclinical Oncology Research.Antioxidants (Basel, Switzerland) · 2025Review
- Apoptotic effects of cold atmospheric pressure plasma on A549 and LL/2 lung carcinoma cell lines.Scientific reports · 2025Article
- Rationales of Cold Plasma Jet Therapy in Skin Cancer.Experimental dermatology · 2025Review
- Autofluorescence-guided Removal of Bacterial Biofilms from Tissues Using Cold Atmospheric Pressure Plasma (CAP).IEEE transactions on radiation and plasma medical sciences · 2024Article
- Reactive oxygen species from non-thermal gas plasma (CAP): implication for targeting cancer stem cells.Cancer cell international · 2024Review
- Effective combination of cold physical plasma and chemotherapy against Ewing sarcoma cells in vitro.Scientific reports · 2024Article
- Plasma-Activated Solutions Mitigates DSS-Induced Colitis via Restoring Redox Homeostasis and Reversing Microbiota Dysbiosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Medical gas plasma technology: Roadmap on cancer treatment and immunotherapy.Redox biology · 2023Review
- Current Status and Future Trends of Cold Atmospheric Plasma as an Oncotherapy.Biomolecules & therapeutics · 2023Review
- Orthopaedic applications of cold physical plasma.EFORT open reviews · 2023Review
- Preclinical Cold Atmospheric Plasma Cancer Treatment.Cancers · 2022Review
- Article
- Plasma oncology: Adjuvant therapy for head and neck cancer using cold atmospheric plasma.Frontiers in oncology · 2022Review
- Therapeutic Effects of Cold Atmospheric Plasma on Solid Tumor.Frontiers in medicine · 2022Review
- Plasma Dermatology: Skin Therapy Using Cold Atmospheric Plasma.Frontiers in oncology · 2022Review
- Cold atmospheric plasma induces apoptosis in human colon and lung cancer cells through modulating mitochondrial pathway.Frontiers in cell and developmental biology · 2022Article
- Gas Plasma Technology Augments Ovalbumin Immunogenicity and OT-II T Cell Activation Conferring Tumor Protection in Mice.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Acidified Nitrite Contributes to the Antitumor Effect of Cold Atmospheric Plasma on Melanoma Cells.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCold Atmospheric Plasma Jet (CAPJ), with ion temperature close to room temperature, has tremendous potential in biomedical engineering, and can potentially offer a therapeutic option that allows cancer cell elimination without damaging healthy tissue. We developed a hand-held flexible device for the delivery of CAPJ to the treatment site, with a modified high-frequency pulse generator operating at a RMS voltage of <1.2 kV and gas flow in the range 0.3-3 l/min. The aims of our study were to characterize the CAPJ emitted from the device, and to evaluate its efficacy in elimination of cancer cells in-vitro and in-vivo. METHODS AND
resultsThe power delivered by CAPJ was measured on a floating or grounded copper target. The power did not drastically change over distances of 0-14 mm, and was not dependent on the targets resistance. Temperature of CAPJ-treated target was 23°-36° C, and was dependent on the voltage applied. Spectroscopy indicated that excited OH- radicals were abundant both on dry and wet targets, placed at different distances from the plasma gun. An in-vitro cell proliferation assay demonstrated that CAPJ treatment of 60 seconds resulted in significant reduction in proliferation of all cancer cell lines tested, and that CAPJ activated medium was toxic to cancer cells. In-vivo, we treated cutaneous melanoma tumors in nude mice. Tumor volume was significantly decreased in CAPJ-treated tumors relatively to controls, and high dose per fraction was more effective than low dose per fraction treatment. Importantly, pathologic examination revealed that normal skin was not harmed by CAPJ treatment.
conclusionThis preliminary study demonstrates the efficacy of flexible CAPJ delivery system against melanoma progression both in-vitro and in-vivo. It is envisioned that adaptation of CAPJ technology for different kinds of neoplasms use may provide a new modality for the treatment of solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.